Skip to main content

Articles

Page 215 of 216

  1. Inflammatory cytokines may negatively influence contractility and contribute to the remodelling process in the failing myocardium. Traditional cardiovascular drugs appear to have little influence on the overal...

    Authors: Jan Kristian Damås, Lars Gullestad and Pål Aukrust
    Citation: Trials 2001 2:271
  2. Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the f...

    Authors: Curt D Furberg and Bertram Pitt
    Citation: Trials 2001 2:205
  3. Antithrombotic treatment is of proven importance in patients with acute coronary syndromes. There is now accumulating evidence from several clinical trials in patients with unstable angina pectoris that the lo...

    Authors: Walter Ageno and Menno V Huisman
    Citation: Trials 2001 2:233
  4. Cardiac rehabilitation (CR) is a commonly used treatment for men and women with cardiovascular disease. To date, no single study has conclusively demonstrated a comprehensive benefit of CR. Numerous individual...

    Authors: Scott A Lear and Andrew Ignaszewski
    Citation: Trials 2001 2:221
  5. Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high i...

    Authors: Thomas W Meade
    Citation: Trials 2001 2:195
  6. Limited information has been published regarding how specific processes for event adjudication can affect event rates in trials. We reviewed nonfatal myocardial infarctions (MIs) reported by site investigators...

    Authors: Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol…
    Citation: Trials 2001 2:187
  7. Clinical events committees (CEC) are used routinely to adjudicate suspected end-points in cardiovascular trials, but little information has been published about the various processes used. We reviewed results ...

    Authors: Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol…
    Citation: Trials 2001 2:180
  8. The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is a prospective, randomized, multicenter clinical trial of carotid endarterectomy (CEA) versus carotid artery stenting (CAS) as preve...

    Authors: Robert W Hobson II, Virginia J Howard, Thomas G Brott, George Howard, Gary S Roubin and Robert DG Ferguson
    Citation: Trials 2001 2:160
  9. Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until...

    Authors: Vernon VS Bonarjee and Kenneth Dickstein
    Citation: Trials 2001 2:151
  10. Randomized trials and observational studies, such as case-control studies, are often seen as opposing approaches. However, in many instances results obtained by different designs may complement each other. For...

    Authors: Frits R Rosendaal
    Citation: Trials 2001 2:109
  11. Data quality assurance and quality control are critical to the effective conduct of a clinical trial. In the present commentary, we discuss our experience in a large, multicenter stroke trial. In addition to s...

    Authors: DeJuran Richardson and Shande Chen
    Citation: Trials 2001 2:115
  12. Women may be at increased risk for venous thromboembolism (VTE) as compared with men. We studied the effects of genetic and biochemical markers of thrombophilia in women, in conjunction with other established ...

    Authors: Joel G Ray, Loralie J Langman, Marian J Vermeulen, Jovan Evrovski, Erik L Yeo and David EC Cole
    Citation: Trials 2001 2:141
  13. During the past decade considerable research has been conducted into the use of cardiac troponins, their diagnostic capability and their potential to allow risk stratification in patients with acute chest pain...

    Authors: Britta U Goldmann, Robert H Christenson, Christian W Hamm, Thomas Meinertz and E Magnus Ohman
    Citation: Trials 2001 2:75
  14. Results from the recent Dietary Approaches to Stop Hypertension (DASH)-Sodium trial provide the latest evidence concerning the effects of dietary patterns and sodium intake on blood pressure. Participants ate ...

    Authors: William M Vollmer, Frank M Sacks and Laura P Svetkey
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:71
  15. Various approaches for catheter ablation of focal initiators of atrial fibrillation or the substrate for maintaining atrial fibrillation have evolved over the past 5 years. Despite these advances, there are st...

    Authors: J Marcus Wharton
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:67
  16. The evidence base for drug treatment of hypertension is strong. Early trials using thiazide diuretics suggested a shortfall in prevention of coronary heart disease. The superiority of newer drugs has been wide...

    Authors: Gordon T McInnes
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:63
  17. Arteriosclerotic vascular disease manifests as heart disease, stroke, aortic aneurysms, and peripheral vascular disease, and is a growing problem world-wide. The preventive efforts made so far have demonstrate...

    Authors: W Virgil Brown
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:12
  18. Only a few randomized clinical trials have been performed so far in heart transplant recipients, mainly because of the relatively small number of heart transplants performed worldwide each year. The main focus...

    Authors: Maria Rosa Costanzo
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:45
  19. The Randomized Aldactone Evaluation Study (RALES) randomized 822 patients to receive 25 mg spironolactone daily and 841 to receive placebo. The primary endpoint was death from all causes. Randomization began o...

    Authors: Janet Wittes, Jolie Palensky, Debra Asner, Desmond Julian, Jean-Pierre Boissel, Curt D Furberg, Henri Kulbertus, Stuart Pocock and Barbara Roniker
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:59
  20. PREVENT was the first prospective, randomized placebo-controlled study of intracoronary beta radiotherapy with 32P. A total of 105 patients with de novo or restenotic lesions, treated by stenting or balloon angio...

    Authors: Albert E Raizner and Grzegorz L Kaluza
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:16
  21. The importance of low-density lipoprotein (LDL) control in the management of patients at high risk of cardiovascular events is unquestionable. The major statin trials have shown that the benefits of LDL loweri...

    Authors: Sergio Fazio and MacRae F Linton
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:8
  22. The fundamental methodological deficiency of megatrials is deliberate reduction of experimental control in order to maximize recruitment and compliance of subjects. Hence, typical megatrials recruit pathologic...

    Authors: Bruce G Charlton
    Citation: Current Controlled Trials in Cardiovascular Medicine 2001 2:2
  23. As the population ages the number of elderly patients presenting with acute myocardial infarction (AMI) will continue to increase. There has been no head-to-head trial of thrombolytic therapy versus primary pe...

    Authors: Vincent S DeGeare and Cindy L Grines
    Citation: Trials 2000 1:146

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.0
    5-year Journal Impact Factor: 2.1
    Source Normalized Impact per Paper (SNIP): 0.733
    SCImago Journal Rank (SJR): 0.812

    Speed 2023
    Submission to first editorial decision (median days): 28
    Submission to acceptance (median days): 129

    Usage 2023
    Downloads: 6,282,238
    Altmetric mentions: 5,569